Mental Health News

NEW YORK--(BUSINESS WIRE)--NYC Health + Hospitals/Gotham Health is expanding access to specialized developmental-behavioral pediatric care....

LOS ANGELES--(BUSINESS WIRE)--While settlements have been reached with Meta Platforms Inc. and Snap Inc. in advance of the second bellwether trial over alleged addictive behaviors and mental health damages affecting young users of social media, lead trial attorney Mark Lanier says the companies must do more. "Families shouldn’t have to go jury by jury to solve a problem this big," says Mr. Lanier. "What these teenagers need is a permanent fix, real design changes that protect kids, not case-by-...

BOSTON--(BUSINESS WIRE)--Seaport Therapeutics Reports Third Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress...

LONDON & JERSEY CITY, N.J.--(BUSINESS WIRE)--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, in partnership with the Depression and Bipolar Support Alliance (DBSA), today released a new report summarizing findings from a national survey of people living with TRD (n=261) and caregivers (n=73) on the self-reported realities of living with a condition that can profoundly affect daily life, revealing th...

DUBLIN--(BUSINESS WIRE)--Alkermes plc (Nasdaq: ALKS) today announced the initiation of a phase 2 study evaluating the safety and efficacy of ALKS 7290 as an adjunctive therapy to antidepressants in adult participants with major depressive disorder (MDD). ALKS 7290 is the company’s investigational orexin 2 receptor (OX2R) agonist in development for the treatment of attention-deficit hyperactivity disorder (ADHD) and for the adjunctive treatment of MDD. “Orexin biology represents a compelling are...

NEW YORK--(BUSINESS WIRE)--Definium Therapeutics, Inc. (NASDAQ: DFTX), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders, today announced that it will host a webcast at 4:30 p.m. EST on Monday, November 9, 2026 to report financial results for the third quarter ended September 30, 2026, and discuss recent business highlights.Listeners can register for the webcast via this link...

BEIJING--(BUSINESS WIRE)--GoodMood Holdings, an AI-powered mental healthcare company, today announced it has completed a financing round of nearly $45 million (RMB 300 million), with participation from Imeik Technology, CSC Financial Capital, Wuxi Binhu Industrial Group, Shandong Development and Unifuture Capital. The company will use the proceeds to advance AI research and development, strengthen its psychiatric and mental health care services, expand its network of in-person specialty clinics...

NEW YORK--(BUSINESS WIRE)--One-Year Follow-up Study Confirms QuantalX’s Delphi-MD Measurements Predict Sustained Response to Ventriculoperitoneal Shunting in NPH...

OSAKA, Japan--(BUSINESS WIRE)--Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”) today announced that ONO-1110, an endocannabinoid modulator, demonstrated efficacy signals in Phase 2 clinical studies in postherpetic neuralgia (PHN), fibromyalgia (FM), and Hunner-type interstitial cystitis (HIC). Additional Phase 2 clinical studies of ONO-1110 were conducted in major depressive disorder (MDD) and social anxiety disorder (SAD). Although the ONO-111...

MIAMI & ROCKVILLE, Md.--(BUSINESS WIRE)--The American Society of Addiction Medicine (ASAM) and OpenEvidence, the most popular AI for doctors in the United States, today announced a collaboration to make ASAM’s clinical guidelines, guidance, and implementation resources accessible through OpenEvidence. This integration enables OpenEvidence’s clinician users to readily access ASAM’s evidence-based guidance for the care of patients with substance use disorders (SUD) and addiction. ASAM’s guidance...